Skip to main content
CSL Behring News)

Global Newsroom

Recent News Releases

For investor-related news, see our ASX releases on our parent company's website:

Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) To Be Covered Under Medicare Part B Effective July 18, Improving Access and Reducing Out-of-Pocket Costs for CIDP Patients
08 Jun 2021


Hizentra will be covered under the same Medicare benefit category as intravenous immune globulin (IVIg), but with the convenience of self-infusing at home

COVID-19 Update
02 Jun 2021

CSL continues to provide medicines to patients around the world.

New Meta-Analysis of Patients with Acute Coronary Syndrome Shows Nearly Half of Recurrent Major Adverse Cardiovascular Events at One Year Occur Within the First 90 Days
16 May 2021


Findings signal need for novel treatment strategies to provide more protection during this high-risk, 90-day period

Lyfebulb and CSL Behring Announce the Winner of the 2021 Transplant Innovation Challenge
13 May 2021


Dr. Minnie Sarwal of NephroSant has been selected to receive the $25,000 Innovation Award

CSL Behring Announces Closing of Global Commercialization and License Agreement with uniQure for etranacogene dezaparvovec
06 May 2021


• Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein that prevents excessive bleeding.

• uniQure will complete the Phase 3 HOPE-B trial and scale up manufacture for initial commercial supply under an agreed plan with CSL Behring.

Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) Label Update Provides New Dosing Guidelines for Physicians, Allowing for Greater Flexibility in Treating CIDP Patients
29 Apr 2021

King of Prussia, Pa

The label update is based on open label extension data from the landmark PATH (Polyneuropathy And Treatment with Hizentra) study

CoVIg-19 Plasma Alliance Announces Topline Results from NIH-Sponsored Clinical Trial of Investigational COVID-19 Hyperimmune Globulin Medicine
02 Apr 2021

Osaka, JAPAN and King of Prussia, Pa., USA

Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its endpoints to show efficacy in adults hospitalized with COVID-19

CSL’s Global Role in Battling COVID-19
02 Apr 2021

Here's how CSL is working around the world with academia, industry and governments to combat COVID-19

Lyfebulb and CSL Behring Launch TransplantLyfe, a First-of-its-Kind Community Engagement Platform for Transplant Patients
25 Jan 2021


• TransplantLyfe is an online community for those living with an organ transplant, their support partners and donors to share experiences, find one-on-one mentorships and help individuals feel safe as they embrace struggles unique to transplantation, regardless of their physical location.

• TransplantLyfe addresses a major unmet need for those living with organ transplantation: most notably, the support and communication gap between individuals with similar experiences in the transplant journey.

Urban League, CSL Behring Partner to Address Community Needs including Public Health, Workforce Diversity, Leadership Development
16 Nov 2020


- 6 Urban League Affiliates across U.S. to participate -- starting with Philadelphia

CSL Behring To Present New Real-World Data on Outcomes Following Acute Coronary Syndrome at American Heart Association Scientific Sessions 2020
10 Nov 2020


Global biotherapeutics leader reinforces commitment to cardiovascular research: Hosts Learning Studio with prominent cardiovascular thought leaders to discuss emerging treatment targets

CSL Behring Publishes Design for First-Ever Outcomes Study of ApoA-I to Reduce Risk of Cardiovascular Events in Heart Attack Patients
05 Nov 2020


The AEGIS-II trial is evaluating the efficacy and safety of CSL112 (apolipoprotein A-1 [human]) during the high-risk 90-day period following a heart attack

Orphan Drug Designation Granted for CSL Behring’s Investigational Plasma-Derived Hemopexin Therapy for Sickle Cell Disease
02 Nov 2020


• Both US and European regulators grant special designation
• Phase 1 clinical development underway for CSL889

CSL Named as One of the World’s Best Employers
29 Oct 2020


- Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year

CSL’s Broad Response to COVID-19 and Advancements Across the Company’s Strategic Scientific Platforms are the Focus of Annual R&D Day
20 Oct 2020


• Vaccine, hyperimmune and monoclonal antibodies all in clinical stages as potential preventative or treatment options in the fight against COVID-19

• Advancements across Cell and Gene Therapy, Recombinant Technology, Plasma Fractionation and Cell and Egg-Based Vaccines scientific platforms all spotlighted including internal progression, acquisitions and alliances

First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine
08 Oct 2020

Osaka, JAPAN and King of Prussia, Pa., USA

• The Alliance’s anti-COVID-19 Hyperimmune Globulin (CoVIg-19) medicine is under evaluation as part of the trial and may become one of the earliest treatments for hospitalized individuals at risk for serious complications of COVID-19
• The CoVIg-19 Plasma Alliance urges anyone who has recovered from COVID-19 to consider donating plasma. To learn more, please visit

U.S. Food and Drug Administration Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) for Prevention of Hereditary Angioedema (HAE) Attacks in Pediatric Patients
28 Sep 2020

HAEGARDA is the first and only subcutaneous prophylactic HAE treatment approved for children 6 years of age and older

CSL Behring Continues to Support Alpha 1 Community, Presents Exciting, New Drug Development Projects at 30th Anniversary of the European Respiratory Society International Congress
04 Sep 2020

MARBURG, Germany

- Bronze sponsor CSL Behring also establishes programme for attendees to support Alpha 1 disease awareness

At White House Roundtable, Plasma Industry Leader & CSL CEO Paul Perreault Urges People to Donate Plasma in the Fight Against COVID-19
30 Jul 2020

• On behalf of the CoVIg-19 Plasma Alliance and other plasma companies, Perreault urges people who have recovered from COVID-19 to consider donating plasma. To learn how and where to donate plasma, please visit

• The more convalescent plasma the industry collects – and the more quickly it does so – directly influences the timeline to deliver a potential hyperimmune globulin for COVID-19.

• The clinical trial, sponsored by The National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH), in which the CoVIg-19 Plasma Alliance will participate is expected to begin soon.

Resources for Media

Fact Sheet           

At-a glance Facts and Figures About CSL Behring    

Brand Center           

Logos, Design Guidelines and more. (Registration required)

See how we are Driven by Our Promise in our 16-page Corporate Brochure.             

CSL Behring Media Contacts

Tom Hushen

Corporate Inquiries
King of Prussia, PA, USA
Phone: +1 267-769-6728

Jennifer Purdue

Hematology, Respiratory and Transplant Inquiries
King of Prussia, PA, USA
Phone: +1 610-878-4802

Valerie Bomberger

Immunology and Cardiovascular & Metabolic Inquiries
King of Prussia, PA, USA
Phone: +1 267-280-3829

Faraz Kermani

Corporate Inquiries, Europe
Hattersheim am Main, Hesse, Germany
Phone: +49 69 305 17169

CSL Behring Production Sites

Sandra Ruckstuhl

Bern, Switzerland
Phone: +41 31-344-1124

Maureen E. Powell

Kankakee, Illinois, USA
Phone: +1 815-935-3120

Stephanie Fuchs

Marburg, Germany
Phone: +49 151 58438860

Christina Hickie

Broadmeadows, Victoria, Australia
Phone: +61 429 609 762

CSL Plasma:
For any CSL Plasma corporate or donation inquiries, please refer to the CSL Plasma website for more information.

Archived News Releases